OxyJet's performance was first assessed through benchtop testing following the UK-MHRA RMCPAP protocol. This was followed by preliminary human testing in healthy volunteers and hypoxemic patients to evaluate safety and usability. A pilot feasibility study involving hypoxemic adult patients in Dhaka, Bangladesh, was then conducted to compare the device's physiological effects with those of standard CPAP therapy.
Ahmed et al. (Wed,) studied this question.